Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alejandro Garciasalas

Internal Medicine Beaufort, SC Medical Doctor

NPI 1811209877 CMS profile 1126605

1 Pinckney Blvd, Beaufort, SC 29902

Open in the dashboard

General payments

$1,389

79 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alejandro Garciasalas of Beaufort, SC is reported in the CMS Open Payments database as having received $1,389 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $294 16
2024 General $446 23
2023 General $268 16
2022 General $137 8
2020 General $86 5
2019 General $158 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alejandro Garciasalas
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Alejandro Garciasalas were reported at $294. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Alejandro Garciasalas Internal Medicine median Middle half National median
2019 $158 $159 $48–$570 $163
2020 $86 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $137 $141 $42–$496 $149
2023 $268 $149 $45–$519 $160
2024 $446 $154 $47–$537 $164
2025 $294 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $237 13 payments
  2. AstraZeneca Pharmaceuticals LP $230 14 payments
  3. Novo Nordisk Inc $159 10 payments
  4. Amgen Inc. $100 6 payments
  5. Exact Sciences Corporation $87 5 payments
  6. Pfizer Inc. $79 5 payments
  7. Dexcom, Inc. $63 2 payments
  8. Abbott Laboratories $48 2 payments
  9. Daiichi Sankyo Inc. $45 2 payments
  10. Currax Pharmaceuticals LLC $45 3 payments
  11. Other $297 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,389 79 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $142 7 payments
  2. RYBELSUS $111 7 payments
  3. Ozempic $111 7 payments
  4. BREZTRI $88 5 payments
  5. EVENITY $78 5 payments
  6. Prolia $78 5 payments
  7. Cologuard Collection Kit $72 4 payments
  8. AIRSUPRA $69 4 payments
  9. Dexcom G6 Transmitter $63 2 payments
  10. JARDIANCE $57 4 payments
  11. Other $935 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 178 drugs

Part D claims

12,630

Median for Internal Medicine: 777

Drug cost

$815,458

Median for Internal Medicine: $73,373

Branded share of claims

18.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 112 $143,235
Ozempic Semaglutide Brand 72 $89,559
Mounjaro Tirzepatide Brand 77 $86,261
Januvia Sitagliptin Phosphate Brand 53 $72,434
Xarelto Rivaroxaban Brand 36 $49,459
Jardiance Empagliflozin Brand 19 $32,308
Trulicity Dulaglutide Brand 20 $26,935
Linzess Linaclotide Brand 29 $22,459
Myrbetriq Mirabegron Brand 28 $19,819
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 79 $15,106

The 10 drugs with the highest cost, of 178 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$203,513

Of which drugs: $36,384

Medicare patients

640

Average age 76

Services billed

3,185

295 women, 345 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 46%
Chronic kidney disease 35%
Diabetes 23%
Ischemic heart disease 20%
Atrial fibrillation 15%
Cancer 13%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 100 100 $28,951
Vaccine for influenza for injection into muscle 90662 Office 77 77 $6,172
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 14 50 $44

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $41
$41 77 —
Veozah
  • Astellas Pharma US Inc $33
$33 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $30
$30 — —
ZEPBOUND
  • Lilly USA, LLC $24
$24 — —
KRYSTEXXA
  • Amgen Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record